A Double-Blind Placebo Controlled Study To Determine the Optimal Immunopharmacological Dose Level of Isoprinosine in Immunodepressed Volunteers
This study has been completed.
Newport Pharmaceuticals International
Information provided by:
NIH AIDS Clinical Trials Information Service
First received: November 2, 1999
Last updated: June 23, 2005
Last verified: June 1989
The objective of this double-blind placebo-controlled study is to evaluate the effect of Isoprinosine in a group of homogenous male volunteers who present with immunologic defects relative to:
- Comparison of total helper and suppressor T-cell number between the groups.
- Comparison of the phytohemagglutinins (PHA) and concanavalin A lymphoproliferative response and natural killer (NK) cell activity between the groups.
- Determination of the clinical course of the volunteers after discontinuance of Isoprinosine.
|Study Design:||Masking: Double-Blind
Primary Purpose: Treatment
|Official Title:||A Double-Blind Placebo Controlled Study To Determine the Optimal Immunopharmacological Dose Level of Isoprinosine in Immunodepressed Volunteers|
Resource links provided by NLM:
U.S. FDA Resources
Further study details as provided by NIH AIDS Clinical Trials Information Service:
Contacts and Locations